SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

PL9 - Invited Science: Neuro-oncology

Event Time: Tuesday April 25, 2017 1:00 pm to 3:00 pm
Topic(s): Neuro-oncology
Director(s):
Description: Top abstracts previously presented at the Society for Neuro-oncology Annual Meeting will be presented by their authors in 20-minute platform presentations. Select abstracts from their "best of" lineups emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of headache with the overall goal of developing more effective prevention and treatment.
Completion Message:
CME Credits: 2
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
1:00 PM - 1:20 PM ACT IV: An International, Double-blind, Phase 3 Trial of Rindopepimut in Newly Diagnosed, EGFRvIII-expressing Glioblastoma Michael Weller MD 
1:20 PM - 1:40 PM Targeting Carcinoma–astrocyte Gap Junctions in Brain Metastasis Mariza Daras MD 
1:40 PM - 2:00 PM Single-cell Profiling of Glioblastoma Biopsies Identifies a Family of Activating PDGF-receptor Deletions Soeren Mueller PhD 
2:00 PM - 2:20 PM Transformation of Tumor Endothelial Cells to Mesenchymal Stem Cell-like Cells Induces Therapy Resistance in Glioblastoma Menggui Huang PhD 
2:20 PM - 2:40 PM Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 (Durvalumab [DUR]) in Patients with Glioblastoma (GBM): Results For Cohort B (DUR Monotherapy), Bevacizumab (BEV) Naïve Patients with Recurrent GBM David Reardon  
2:40 PM - 3:00 PM Redefining the Cellular Architecture of Adult and Pediatric Glioblastomas Through Large-scale Single-cell Analyses Mariella Filbin MD, PhD 

Disclosures

Speaker Disclosure
Mariza Daras, MD Dr. Daras has nothing to disclose.

Mariella Filbin, MD, PhD Dr. Filbin has nothing to disclose.

Menggui Huang, PhD Dr. Huang has nothing to disclose.

Soeren Mueller, PhD Dr. Mueller has nothing to disclose.

David Reardon Dr. Reardon has received personal compensation for activities with Merck Schering, Genentech, EMD Serono, Stemline Therapeutics, and Momenta Pharmaceuticals as a speaker and/or advisory board participant.

Michael Weller, MD Dr. Weller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, BMS, Celldex, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, Orbus, Pfizer, Progenics, Roche, Teva and Tocagen. Dr. Weller has received research support from Abbvie, Acceleron, Actelion, Bayer, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur, Roche and Tragara.

Register Now

Related Courses

Sunday April 22, 2018

9:15 AM-12:00 PM
PL2 Presidential Plenary Session

Wednesday April 25, 2018

1:00 PM-3:00 PM
C148 Neurologic Consultations in Cancer Patients I Amy Pruitt MD
3:30 PM-5:30 PM
C163 Neurologic Consultations in Cancer Patients II Patrick Wen MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C177 Neuro-oncology in 2018: Navigating Current Trends Maciej Mrugala MD
1:00 PM-3:00 PM
C189 Neuro-oncologic Predicaments in the Hospital Setting Na Tosha Gatson MD, PhD
3:30 PM-5:30 PM
N6 Neuroscience in the Clinic: Neurologic Complications of Cancer Immunotherapy: A New Frontier in Neuro-Inflammation Antonio Omuro MD,
Andreas Hottinger MD

MEMBER LOG IN

Forgot Password?